Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 40OTHER_GOV 3NIH 2UNKNOWN 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Vomiting 1Squamous Cell Carcinoma of Head and Neck 1Radiation Injuries 1Nausea 1

Interventions

Paclitaxel 20Capecitabine 18S 1 (combination) 17Cisplatin 15Oxaliplatin 11apatinib 8Radiotherapy, Intensity-Modulated 8Epirubicin 8Docetaxel 8Carboplatin 8Radiotherapy 7Irinotecan 7titanium silicide 6sintilimab 6pyrotinib 6nimotuzumab 6anlotinib 6Albumin-Bound Paclitaxel 6130-nm albumin-bound paclitaxel 6nedaplatin 5camrelizumab 5Temozolomide 5Etoposide 5Drug Therapy 5Bevacizumab 5nabiximols 4Vinorelbine 4Trastuzumab 4Radiation Dose Hypofractionation 4Radiation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
UNKNOWN × Olanzapine × Clear all
NCT05202275 2022-01-21

The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs

ChineseAMS

Phase 2 Unknown
43 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nausea, Radiation Injuries, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡